ArticleExperimental eye research2025
TGFβ2 alters segmental outflow and ECM ultrastructure in the trabecular meshwork.
Article in Experimental eye research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel Role for CGRP in Aqueous Humor Outflow.Investigative ophthalmology & visual science · 2026Article
- Segmental Outflow and Trabecular Meshwork Stiffness in an Ocular Hypertensive Mouse Model.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
TGFβ2 is a well-known contributor to extracellular matrix (ECM) changes in the trabecular meshwork (TM). TGFβ2 is increased in the aqueous humor (AH) of primary open angle glaucoma patients and the addition of TGFβ2 to primary human TM cells in culture induces pathogenic changes similar to what is seen in the TM of ocular hypertensive and glaucomatous eyes. Overexpression of a bioactivated form of TGFβ2 using adenovirus 5 (Ad5.TGFβ2) in the TM has previously been described as an inducible mouse model of ocular hypertension and has been utilized for multiple studies to help understand the pathogenies of TGFβ2-induced TM damage and elevated intraocular pressure (IOP). Ad5.TGFβ2 is known to elevate IOP, decrease outflow facility, and increase expression of ECM proteins in the TM. Here, we further analyze the effects of overexpression of TGFβ2 by Ad5 in the TM. We found Ad5.TGFβ2 increases expression of macrophage marker Iba1 and increases expression of ECM proteins fibronectin and collagen 1 compared to Ad5.Null injected controls. In addition, overexpression of TGFβ2 by Ad5 led to a decrease in segmental AH flow regions compared to Ad5.Null control eyes. Ultrastructure analysis of the Ad5.TGFβ2 injected eyes also show significantly more areas occupied by ECM material as well as the development of more smaller giant vacuoles compared to Ad5.Null injected eyes. These data in combination with prior research using Ad5.TGFβ2, establish the use of intraocular injection of Ad5.TGFβ2 as an appropriate mouse model of ocular hypertension to study aqueous humor outflow and its mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.